DaVita Inc. (DVA)
Automate Your Wheel Strategy on DVA
With Tiblio's Option Bot, you can configure your own wheel strategy including DVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DVA
- Rev/Share 163.3974
- Book/Share 20.9148
- PB -40.3495
- Debt/Equity -46.1261
- CurrentRatio 1.2509
- ROIC 0.1125
- MktCap 10252145000.0
- FreeCF/Share 22.1651
- PFCF 5.8277
- PE 12.5375
- Debt/Assets 0.7197
- DivYield 0
- ROE 3.9358
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates
Published: May 30, 2025 by: PRNewsWire
Sentiment: Neutral
DENVER , May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita.
Read More
DaVita: International Expansion And Buybacks Will Boost Returns
Published: May 27, 2025 by: Seeking Alpha
Sentiment: Positive
International expansion continues with new clinics in Brazil, Ecuador, Chile, and Colombia, supporting long-term growth beyond the US market. DaVita's stock offers a 10% FCF yield, and the share count is decreasing at a fast pace. On top of share buybacks, the company will grow revenues above inflation due to its defensive business model and 35% market share.
Read More
DaVita Inc. Announces Upsize and Pricing of $1 Billion Senior Notes Offering
Published: May 20, 2025 by: PRNewsWire
Sentiment: Neutral
DENVER , May 20, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today the upsize and pricing of its previously announced private offering (the "offering") of its 6.750% senior notes due 2033 (the "2033 notes"). The aggregate principal amount of the 2033 notes offered in the offering was increased from $750 million to $1 billion, and the 2033 notes were priced at 100.000% of their face amount to yield a 6.750% coupon.
Read More
DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship
Published: May 20, 2025 by: PRNewsWire
Sentiment: Neutral
Captures key initiatives achieved in 2024, driving 2025 ESG goals DENVER , May 20, 2025 /PRNewswire/ -- Today, DaVita (NYSE: DVA) published its Community Care report, underpinning its long-standing commitment to corporate citizenship and highlighting strides made towards ambitious Environmental, Social and Governance (ESG) goals set to be achieved this year. Milestones and achievements reflect calendar year 2024.
Read More
Here's Why DaVita HealthCare (DVA) is a Strong Growth Stock
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
DaVita Stock Down Despite Q1 Earnings Beat, Margins Contract
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Negative
Strength in revenue per treatment and dialysis patient service revenues drives DVA's first-quarter 2025 performance despite a year-over-year decline in normalized non-acquired treatment.
Read More
Can Revenue Cycle Operations Drive DVA Stock Before Q1 Earnings?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Continued strength in revenue cycle operations is likely to have boosted DaVita's top line in the first quarter despite supply challenges weighing on its performance.
Read More
DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
DaVita HealthCare (DVA) closed the most recent trading day at $143.96, moving +0.94% from the previous trading session.
Read More
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the most recent trading session, DaVita HealthCare (DVA) closed at $151.37, indicating a +0.39% shift from the previous trading day.
Read More
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
DVA's stable core business and global expansion are offset by rising labor costs and declining commercial mix, creating a mixed outlook for investors.
Read More
DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2025
Published: March 06, 2025 by: PRNewsWire
Sentiment: Neutral
DENVER , March 6, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at the Barclays Global Healthcare Conference 2025 on Tuesday, March 11, 2025, at 9:00 a.m. EDT. To view the live webcast, visit the Barclays page and create a free registration.
Read More
YMCA of the USA Deepens Collaboration with DaVita to Drive Kidney Health Initiatives in Seven Communities
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
CHICAGO and DENVER, Feb. 27, 2025 (GLOBE NEWSWIRE) -- YMCA of the USA (Y-USA), the national resource office for the 2,600+ YMCAs across the country, is excited to expand its collaboration with DaVita, a leading provider of comprehensive kidney care, to advance chronic disease education and prevention for individuals and their families who are either managing or at risk for chronic kidney disease (CKD). CKD disproportionately affects individuals with risk factors such as hypertension and diabetes.
Read More
Here's why this Warren Buffett stock plunged 11% in a day
Published: February 17, 2025 by: Finbold
Sentiment: Negative
Shares of Davita Inc. (NYSE: DVA) plunged 11% on February 14, as the dialysis provider issued a weaker-than-expected 2025 earnings outlook, citing rising patient care costs, supply constraints, and ongoing dialysis center closures.
Read More
Why DaVita Inc Stock Is Plummeting Today
Published: February 14, 2025 by: The Motley Fool
Sentiment: Negative
Shares of DaVita Inc (DVA -11.09%) are trading lower on Friday. The company's stock lost 11.1% as of market close but lost as much as 15.2% earlier in the day.
Read More
DaVita's stock leads S&P 500 decliners after Berkshire pares stake. Its soft guidance isn't helping.
Published: February 14, 2025 by: Market Watch
Sentiment: Negative
DaVita shares were tumbling 13.5% Friday to lead S&P 500 decliners, after Warren Buffett's Berkshire Hathaway pared its stake in the provider of kidney dialysis.
Read More
Here's why Warren Buffett dumped $31 million worth of this stock
Published: February 14, 2025 by: Finbold
Sentiment: Negative
Warren Buffett, the ‘Oracle of Omaha', managed to attain a roughly $142 billion net worth by consistently outperforming the markets. The Berkshire Hathaway (NYSE: BRK.B) chief executive officer (CEO) and chairman did so by utilizing a careful, level-headed approach to investing.
Read More
DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
DaVita Inc. (NYSE:DVA ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Nic Eliason - Group VP, IR Javier Rodriguez - CEO Joel Ackerman - CFO Conference Call Participants Joanna Gajuk - Bank of America AJ Rice - UBS Pito Chickering - Deutsche Bank Justin Lake - Wolfe Research Andrew Mok - Barclays Ryan Langston - TD Cowen Operator Good evening. My name is Michelle, and I will be your conference facilitator today.
Read More
Berkshire sells some DaVita shares, cuts stake to 45%
Published: February 13, 2025 by: Reuters
Sentiment: Negative
Berkshire Hathaway said on Thursday night it sold 203,091 shares of DaVita , reducing its stake in the kidney dialysis services provider to about 35.89 million shares, a 45% stake worth nearly $6.4 billion.
Read More
DVA Q4 Estimates Unchanged Before Earnings: How to Play the Stock?
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Continued strength in RPT is likely to have boosted DaVita's top line in the fourth quarter despite supply challenges weighing on its performance.
Read More
About DaVita Inc. (DVA)
- IPO Date 1995-10-31
- Website https://www.davita.com
- Industry Medical - Care Facilities
- CEO Mr. Javier J. Rodriguez
- Employees 76000